Literature DB >> 10823794

Escherichia coli O157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2.

A Donohue-Rolfe1, I Kondova, S Oswald, D Hutto, S Tzipori.   

Abstract

Infection with Escherichia coli O157:H7 can lead to hemolytic uremic syndrome (HUS) in some children. Epidemiologic data suggest that Shiga toxin (Stx) 2-producing strains are more frequently associated with HUS than are Stx1-producing strains. Less clear is whether strains that express Stx2 alone are more frequently associated with HUS than strains that express Stx1 and Stx2. Isogenic mutants 933stx1- and 933stx2- were produced from strain 933 (Stx1 and Stx2 producer), and 86-24stx2- was produced from strain 86-24 (Stx2 producer). Neurologic lesions or symptoms developed in 18 (90%) of 20 gnotobiotic piglets orally infected with strain 86-24, in 15 (85%) of 18 infected with mutant 933stx1-, in 9 (31%) of 29 infected with strain 933, in 0 of 5 infected with mutant 86-24stx2-, and in 0 of 6 infected with mutant 933stx2-. It was concluded that strains expressing Stx2 alone are more neurotropic for piglets when fed orally than are those strains expressing Stx1 and 2, whereas Stx1-producing strains induce only diarrhea. It is also conceivable that strains that produce Stx2 may constitute a significant predictive risk factor for HUS in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823794     DOI: 10.1086/315421

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  52 in total

1.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Hfq virulence regulation in enterohemorrhagic Escherichia coli O157:H7 strain 86-24.

Authors:  Melissa M Kendall; Charley C Gruber; David A Rasko; David T Hughes; Vanessa Sperandio
Journal:  J Bacteriol       Date:  2011-10-07       Impact factor: 3.490

3.  A Putative Microcin Amplifies Shiga Toxin 2a Production of Escherichia coli O157:H7.

Authors:  Hillary M Mosso; Lingzi Xiaoli; Kakolie Banerjee; Maria Hoffmann; Kuan Yao; Edward G Dudley
Journal:  J Bacteriol       Date:  2019-12-06       Impact factor: 3.490

4.  Influence of RNase E deficiency on the production of stx2-bearing phages and Shiga toxin in an RNase E-inducible strain of enterohaemorrhagic Escherichia coli (EHEC) O157:H7.

Authors:  Thujitha Thuraisamy; Patricia B Lodato
Journal:  J Med Microbiol       Date:  2018-04-05       Impact factor: 2.472

5.  An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin.

Authors:  Miho Watanabe-Takahashi; Toshio Sato; Taeko Dohi; Noriko Noguchi; Fumi Kano; Masayuki Murata; Takashi Hamabata; Yasuhiro Natori; Kiyotaka Nishikawa
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

Review 6.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

7.  Shiga Toxin Type 1a (Stx1a) Reduces the Toxicity of the More Potent Stx2a In Vivo and In Vitro.

Authors:  Courtney D Petro; Eszter Trojnar; James Sinclair; Zhi-Mei Liu; Mark Smith; Alison D O'Brien; Angela Melton-Celsa
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

8.  Infection of Immunocompetent Conventional Mice with Shiga Toxin-Producing E. coli: The DSS + STEC Model.

Authors:  Gregory Hall; Shinichiro Kurosawa; D J Stearns-Kurosawa
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Authors:  S Barnoy; K I Jeong; R F Helm; A E Suvarnapunya; R T Ranallo; S Tzipori; M M Venkatesan
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.